Indeed, a major barrier to developing effective therapies in tRCC has been an incomplete understanding of the oncogenic pathways driven by the TFE3 fusion. The gene discussed is TFE3; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.